# reload+after+2024-01-19 23:47:25.832942
address1§9715 Key West Avenue
city§Rockville
state§MD
zip§20850
country§United States
phone§301 838 2500
website§https://www.supernus.com
industry§Drug Manufacturers—Specialty & Generic
sector§Healthcare
longBusinessSummary§Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; and SPN-820, a product candidate in Phase II clinical trials for treating resistant depression. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.
fullTimeEmployees§612
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Jack A. Khattar', 'age': 62, 'title': 'Founder, President, CEO, Secretary & Director', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 1628967, 'exercisedValue': 10792910, 'unexercisedValue': 21653200}, {'maxAge': 1, 'name': 'Mr. Timothy C. Dec', 'age': 64, 'title': 'Senior VP & CFO', 'yearBorn': 1959, 'fiscalYear': 2022, 'totalPay': 635430, 'exercisedValue': 0, 'unexercisedValue': 224825}, {'maxAge': 1, 'name': 'Dr. Padmanabh P. Bhatt Ph.D.', 'age': 66, 'title': 'Chief Scientific Officer & Senior VP of Intellectual Property', 'yearBorn': 1957, 'fiscalYear': 2022, 'totalPay': 594136, 'exercisedValue': 334602, 'unexercisedValue': 1817955}, {'maxAge': 1, 'name': 'Mr. Frank  Mottola', 'age': 51, 'title': 'Senior Vice President of Quality, GMP Operations & Information Technology', 'yearBorn': 1972, 'fiscalYear': 2022, 'totalPay': 490873, 'exercisedValue': 0, 'unexercisedValue': 1078405}, {'maxAge': 1, 'name': 'Dr. Jonathan  Rubin M.D., MBA', 'age': 62, 'title': 'Senior VP of Research & Development and Chief Medical Officer', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 594648, 'exercisedValue': 0, 'unexercisedValue': 125475}, {'maxAge': 1, 'name': 'Mr. Kevin T. Anderson', 'age': 61, 'title': 'Compliance Officer', 'yearBorn': 1962, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Todd  Horich M.B.A., Ph.D.', 'title': 'Senior Vice President of Marketing & Market Access', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Taylor  Raiford', 'title': 'Senior Vice President of Sales', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Bryan A. Roecklein Ph.D.', 'title': 'Senior Vice President of Corporate Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Tami T. Martin Esq., R.N.', 'age': 68, 'title': 'Senior Vice President of Regulatory Affairs', 'yearBorn': 1955, 'fiscalYear': 2022, 'totalPay': 508501, 'exercisedValue': 112515, 'unexercisedValue': 1054380}]
auditRisk§9
boardRisk§4
compensationRisk§5
shareHolderRightsRisk§7
overallRisk§6
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§1.004
priceToSalesTrailing12Months§2.4545321
currency§USD
dateShortInterest§1702598400
forwardEps§1.9
pegRatio§7.6
exchange§NGM
quoteType§EQUITY
shortName§Supernus Pharmaceuticals, Inc.
longName§Supernus Pharmaceuticals, Inc.
firstTradeDateEpochUtc§1335879000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§c9cc5841-b3c3-35e0-9fd3-f79c8df8db94
gmtOffSetMilliseconds§-18000000
targetHighPrice§43.0
targetLowPrice§40.0
targetMeanPrice§42.0
targetMedianPrice§43.0
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§3
quickRatio§1.189
grossMargins§0.85733
ebitdaMargins§0.18079
trailingPegRatio§None
